⚕ GalenOps CRO console
← SITE014 (NLD)

SITE014-0336

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE014 (NLD) (Dr. Moreau) · consented 2023-04-09
Adverse events
8
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-04-19 (study day 4); relationship: N

moderate assessed 2026-08-18

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-04-23 (study day 8); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-05-03 (study day 18); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-26 (study day 41); relationship: N

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-05-26 (study day 41); relationship: N

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-29 (study day 44); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-06-05 (study day 51); relationship: N

mild assessed 2026-08-18

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-06-25 (study day 71); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.